Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the transaction, the chief executive officer now directly owns 250,000 shares in the company, valued at approximately $17,885,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Spark Therapeutics, Inc. (ONCE) opened at $72.65 on Tuesday. Spark Therapeutics, Inc. has a fifty-two week low of $47.03 and a fifty-two week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. Spark Therapeutics’s revenue was up 45.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.07) earnings per share. analysts expect that Spark Therapeutics, Inc. will post -7.62 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in ONCE. BlackRock Inc. grew its holdings in Spark Therapeutics by 11,332.0% during the 1st quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after acquiring an additional 1,824,117 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Spark Therapeutics during the 2nd quarter worth $30,848,000. Jennison Associates LLC acquired a new position in Spark Therapeutics during the 3rd quarter worth $27,239,000. JPMorgan Chase & Co. grew its holdings in Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares in the last quarter. Finally, Sectoral Asset Management Inc acquired a new position in Spark Therapeutics during the 2nd quarter worth $6,052,000. 77.94% of the stock is owned by institutional investors.
Several research firms have recently issued reports on ONCE. Cantor Fitzgerald dropped their price objective on shares of Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating for the company in a research report on Friday, October 13th. Cowen and Company reissued a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Barclays PLC increased their price objective on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Chardan Capital reissued a “buy” rating and issued a $100.00 price objective on shares of Spark Therapeutics in a research report on Friday, October 13th. Finally, Zacks Investment Research raised shares of Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have assigned a buy rating to the stock. Spark Therapeutics presently has a consensus rating of “Buy” and an average price target of $90.36.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.